作者
Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
发表日期
1998/5/21
期刊
New England Journal of Medicine
卷号
338
期号
21
页码范围
1498-1505
出版商
Massachusetts Medical Society
简介
Background
Activation of platelets is central to the pathophysiology of unstable angina. We studied whether inhibition of the final common pathway for platelet aggregation with tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, would improve clinical outcome in this condition.
Methods
In a double-blind study, we randomly assigned 3232 patients who were already receiving aspirin to additional treatment with intravenous tirofiban or heparin for 48 hours. The primary end point was a composite of death, myocardial infarction, or refractory ischemia at 48 hours.
Results
The incidence of the composite end point was 32 percent lower at 48 hours in the group that received tirofiban (3.8 percent, vs. 5.6 percent with heparin; risk ratio, 0.67; 95 percent confidence interval, 0.48 to 0.92; P=0.01). Percutaneous revascularization was performed in 1.9 percent of the patients during the first 48 hours. At 30 days, the …
引用总数
学术搜索中的文章
Platelet Receptor Inhibition in Ischemic Syndrome … - New England Journal of Medicine, 1998
O Bazzino, P Aylward, A Hains, J Slany, K Steinbach… - New England Journal of Medicine, 1998
PRISM study investigators - N Engl J Med, 1998